Valneva
VALN | NASDAQ
$5.73
+$0.07 (+1.24%)
At close: Nov 16, 2026, 3:59 PM ET
$5.67
-$0.06 (-1.05%)
After-hours:
Nov 16, 2026, 5:31 PM ET
+1.24%
(1D)No price chart data available for 1D timeframe.
Rating
22.5
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #974/1021 (Top 95%)
Key Statistics
Market Data
Market Cap $545.08M
1D Range
5.59 5.74
52W Range
4.78 11.99
Valuation (TTM)
PE -2.70
PB 5.89
EV/EBITDA -6.07
Valuation (NTM)
Forward PE 8.79
Forward PEG 0.32
Price Target $11.00
Cash Flow
FCF Yield -17.3%
SBC Adj. FCF Yield -17.3%
SBC Impact N/A
Margins
Gross Margin 16.4%
Operating Margin -80.9%
FCF Margin -59.7%
Growth (CAGR)
Revenue 3Y | 5Y -25.1% |
5.5%
Dil EPS 3Y | 5Y -61.1% |
14.9%
FCF 3Y | 5Y 57.1% |
25.1%
Returns
ROA -40.6%
ROE -152.2%
ROIC -40.5%
Financial Health
Net Debt
€65.24M ($74.51M)
Current Ratio 2.16
Interest Coverage -3.05
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical optio...
Sector Healthcare
Industry Biotechnology
Employees 674
IPO Date May 5, 2021
Website valneva.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Sell
Price Target
$11.00
Upside
+91.97%
Buy (0)
Hold (0)
Sell (1)
Add to Watchlist
Select watchlists to add or remove VALN